Vaxart Inks Antiviral Asset Licensing Pact With Altesa Biosciences

Comments
Loading...
  • Vaxart Inc VXRT has granted Altesa Biosciences Inc an exclusive worldwide license to develop and commercialize Vaxart's patented formulation of the capsid-binding Vapendavir, a clinical-stage broad-spectrum antiviral.
  • Under the terms of the agreement, Vaxart is eligible to receive up to $130 million in milestone payments and tiered royalties ranging from the low-single to low-double digits on product sales for multiple indications.
  • Vaxart acquired Vapendavir in 2018 as part of the merger with Aviragen Therapeutics Inc
  • Price Action: VXRT shares are down 1.36% at $7.26 during the market session on the last check Wednesday.
VXRT Logo
VXRTVaxart Inc
$0.32004.40%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
6.07
Growth
-
Quality
-
Value
65.85
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: